Drugs / ALT-100
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05426746 | Jul 2022 → May 2023 | acute respiratory distress syndrome | Aqualung Therapeutics Corp. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05938036 | Dec 2023 → May 2027 expected | adult acute respiratory distress syndrome | Aqualung Therapeutics Corp. | Active not recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2025-09-15 | Aqualung Therapeutics Corp. | Regulatory FDA aqualungtherapeutics.com ↗
Aqualung Therapeutics has received clearance from the U.S. Food and Drug Administration (FDA) to initiate a Phase 2a clinical study of ALT-100, its lead monoclonal antibody targeting extracellular NAMPT (eNAMPT), in patients with progressive pulmonary fibrosis (PPF). |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2025-09-15 | Aqualung Therapeutics Corp. | FDA aqualungtherapeutics.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ALT-100 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05426746 ↗ |
| Modality | Monoclonal antibody | “ALT-100 is a monoclonal antibody” NCT05426746 ↗ |
| Route | Intravenous | “administered by intravenous infusion” NCT05426746 ↗ |